To assess the efficacy and safety of artemether emulsion in patients with papulopustular rosacea. A total of 130 (randomized 1:1) were externally administered either artemether emulsion (1%) or metronidazole emulsion (3%) twice daily for 4 weeks with an open-label 8-week follow-up. The primary endpoints included the proportion of patients who achieved clinical effective responses, as well as erythema and papule and pustule score at week 4. Numerically more patients achieved an effective response at week 4 with artemether emulsion (87.1%) than metronidazole emulsion (80.0%) ( > .05). Patients with artemether emulsion had comparable baseline erythema score (2.45 ± 0.67 versus 2.42 ± 0.70,  = .809) and papule and pustule score (2.11 ± 0.96 versus 2.32 ± 0.83,  = .264), but significantly lower papule and pustule score (0.21 ± 0.52 versus 0.42 ± 0.83,  = .001) and comparable erythema score (0.53 ± 0.88 versus 0.62 ± 0.88,  = .999) compared to patients with metronidazole emulsion at week 4. There was a significantly higher proportion of patients with metronidazole emulsion relapse compared to metronidazole emulsion during the open-label 8-week follow-up period (21.6% versus 2.4%,  < .01). Artemether emulsion improved papulopustular rosacea in the metronidazole emulsion group as early as 4 weeks, but its beneficial effect was maintained through the 8-week follow-up period compared to metronidazole emulsion.

Download full-text PDF

Source
http://dx.doi.org/10.1080/09546634.2019.1610549DOI Listing

Publication Analysis

Top Keywords

artemether emulsion
20
metronidazole emulsion
20
papule pustule
12
pustule score
12
emulsion
10
papulopustular rosacea
8
open-label 8-week
8
8-week follow-up
8
proportion patients
8
patients achieved
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!